Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CDTX
1326
DELISTED
Cidara Therapeutics
CDTX
| $17.3M | ﹤0.01% |
78,322
-35,057
| -31% | -$5.67M |
|
1327
State Street SPDR S&P Bank ETF
KBE
$1.73B
| $17.3M | ﹤0.01% |
284,992
+110,719
| +64% | +$6.52M |
|
1328
Pool Corp
POOL
$7.16B
| $17.2M | ﹤0.01% |
75,232
+1,700
| +2% | +$442K |
|
1329
Commercial Metals
CMC
$7.91B
| $17.2M | ﹤0.01% |
248,372
-10,637
| -4% | -$666K |
|
1330
PUT
Celsius Holdings
CELH
$6.86B
| $17.2M | ﹤0.01% |
375,000
-150,000
| -29% | -$7.56M |
|
1331
BioMarin Pharmaceuticals
BMRN
$13.6B
| $17.1M | ﹤0.01% |
288,547
-566,041
| -66% | -$30.8M |
|
1332
PUT
Pan American Silver
PAAS
$22.2B
| $17.1M | ﹤0.01% |
+330,000
| New | +$13.8M |
|
1333
Kinetik
KNTK
$4.15B
| $17.1M | ﹤0.01% |
473,980
+158,279
| +50% | +$5.72M |
|
1334
CALL
GameStop
GME
$8.33B
| $17.1M | ﹤0.01% |
850,000
+14,500
| +2% | +$325K |
|
1335
Iridium Communications
IRDM
$5.32B
| $17M | ﹤0.01% |
980,847
+442,985
| +82% | +$7.83M |
|
1336
Generac Holdings
GNRC
$13.1B
| $17M | ﹤0.01% |
124,913
+22,296
| +22% | +$3.6M |
|
1337
Sanmina
SANM
$11.5B
| $17M | ﹤0.01% |
113,473
+34,494
| +44% | +$5.09M |
|
1338
Ares Capital
ARCC
$14.2B
| $17M | ﹤0.01% |
841,558
+140,099
| +20% | +$2.83M |
|
1339
EPAM Systems
EPAM
$5.07B
| $17M | ﹤0.01% |
83,089
-615,524
| -88% | -$110M |
|
1340
HealthEquity
HQY
$8.7B
| $17M | ﹤0.01% |
185,104
-29,187
| -14% | -$2.79M |
|
1341
Avis
CAR
$4.9B
| $16.9M | ﹤0.01% |
131,836
+104,887
| +389% | +$14.6M |
|
1342
Medpace
MEDP
$16.7B
| $16.9M | ﹤0.01% |
30,047
+1,828
| +6% | +$1.04M |
|
1343
Boise Cascade
BCC
$2.89B
| $16.9M | ﹤0.01% |
229,057
-69,140
| -23% | -$5.04M |
|
1344
Owens Corning
OC
$12.3B
| $16.8M | ﹤0.01% |
150,293
-93,175
| -38% | -$10.9M |
|
1345
Vanguard Long-Term Corporate Bond ETF
VCLT
$8.77B
| $16.7M | ﹤0.01% |
220,670
+211,023
| +2,187% | +$16.3M |
|
1346
Western Alliance Bancorporation
WAL
$8.89B
| $16.7M | ﹤0.01% |
199,073
-17,646
| -8% | -$1.43M |
|
1347
PTC Therapeutics
PTCT
$6.17B
| $16.7M | ﹤0.01% |
220,196
-19,453
| -8% | -$1.41M |
|
1348
CALL
Warner Bros
WBD
$69.3B
| $16.7M | ﹤0.01% |
580,000
-745,000
| -56% | -$17.4M |
|
1349
PUT
Enphase Energy
ENPH
$5.53B
| $16.7M | ﹤0.01% |
521,000
-115,000
| -18% | -$3.72M |
|
1350
A.O. Smith
AOS
$8.49B
| $16.6M | ﹤0.01% |
248,323
+10,639
| +4% | +$719K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.